Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM1975O)

Drug Name
Cilnidipine Drug Info
Synonyms
Atelec; Cinaldipine; Cinalong; Siscard; Cilnidipine [INN]; FRC 8653; Atelec (TN); FRC-8653; Cilnidipine (JAN/INN); (+-)-(E)-Cinnamyl 2-methoxyethyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate; 1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl (2E)-3-phenyl-2-propenyl ester; 2-methoxyethyl (2E)-3-phenylprop-2-en-1-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate; 3-O-(2-methoxyethyl) 5-O-[(E)-3-phenylprop-2-enyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate
Cross-matching ID
PubChem CID
5282138
ChEBI ID
CHEMBL452076
CAS Number
CAS 132203-70-4
TTD Drug ID
D0N3SR
VARIDT Drug ID
DR01023
INTEDE Drug ID
DR0323

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
ECM-receptor interaction 2.11 0.00e+0 80/88 (90.91%) LAMB3;HSPG2;COMP;...
Protein processing in endoplasmic reticulum 1.94 1.22e-2 127/171 (74.27%) PDIA3;MOGS;GANAB;...
Cysteine and methionine metabolism 1.90 1.22e-2 43/50 (86%) BCAT1;CBS;PSAT1;...
Various types of N-glycan biosynthesis 1.88 1.83e-2 26/39 (66.67%) ALG3;HEXB;HEXA;...
Mineral absorption -1.72 4.64e-2 48/60 (80%) FXYD2;ATP2B4;HEPH;...
Butanoate metabolism -1.75 3.97e-2 23/28 (82.14%) GAD1;AACS;ACAT2;...
RNA polymerase -1.79 2.58e-2 23/31 (74.19%) POLR2C;POLR2G;POLR2F;...
Ribosome -1.94 4.64e-3 113/158 (71.52%) RPLP0;RPL19;RPS3;...
Synthesis and degradation of ketone bodies -2.05 0.00e+0 9/10 (90%) ACAT2;HMGCS1
Oxidative phosphorylation -2.06 0.00e+0 93/133 (69.92%) NDUFS4;ATP5MC1;ATP5PD;...
Terpenoid backbone biosynthesis -2.17 0.00e+0 18/22 (81.82%) PCYOX1;FDPS;DHDDS;...
Steroid biosynthesis -2.31 0.00e+0 19/20 (95%) EBP;DHCR7;SC5D;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 6.66uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 10uM 6H